We present a sectioning and bonding technology to make ultrahigh density microarrays of solid samples, cutting edge matrix assembly (CEMA). Maximized array density is achieved by a scaffold-free, self ...

Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian influenza A (H7N9) vaccine delivered intradermally by Vaxxas’ high-density microarray ...

Publication in PLoS Medicine reveals groundbreaking clinical research on broad potential of novel high-density microarray patch (HD-MAP) to efficiently deliver vaccines directly to the skin, enhancing ...

Recent activity in the microarray arena reaffirms Affymetrix's (Santa Clara, CA) stronghold on the high-density DNA array market. However, although the demand for microarrays is expected to double in ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication in the journal PLoS Medicine of groundbreaking clinical research indicating ...